Key facts
- Spolia Therapeutics’s last known valuation is $142.5M (Mar 2026).
- It has raised $80.0M; the latest was Early Stage VC ($60.0M) in Mar 2026.
- Notable investors include Hatteras Venture Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Spolia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Spolia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spolia Therapeutics
Developer of therapeutic biotechnology systems intended for treating neurometabolic and neurodegenerative disorders. The company targets metabolic dysregulation using precision-focused and science-driven approaches to develop advanced therapies, enabling patients and clinicians to access targeted treatment options supported by cellular and molecular research.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 10
- Website
- spoliatx.com/
- Ownership
- Privately Held (backing)
Spolia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spolia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spolia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.